                         SEQUENCE LISTING

<110>  SALIMETRICS, LLC
       PETERSON, Jon  Eric
       LI, Daming
       LIU, Xiuwen
       CHOU, Meng-Yun  Sandy
       SARD, Howard Paul
 
<120>  MELATONIN MONOCLONAL ANTIBODY, DETECTION, METHODS AND USES 
       THEREOF

<130>  023959-0429598

<140>  PCT/US2014/29257
<141>  2014-04-14

<150>  61/794,713
<151>  2013-04-15

<150>  61/809,751
<151>  2013-04-08

<160>  20    

<170>  PatentIn version 3.5

<210>  1
<211>  429
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Heavy chain antibody

<400>  1
atggagactg ggctgcgctg gcttctcctg gtcgctgtgc tcaaaggtgt ccagtgtcag       60

tcgttggagg agtccggggg agacctggtc aagcctgggg catccctgac actcacctgc      120

acagcctctg gattctcttt tagtcgctat gattatatgt gctgggtccg ccaggctcca      180

gggaaggggc tggagtggat cgcaagtatt tatgttggta gtggtgtcac ttactactcg      240

acctgggcga gaggccgatt cgccatctcc caaacctcgt cgaccacgat gactctacaa      300

atgaccagtc tgacagccgc ggacacggcc acttacttct gtgcgagatt tcatggtcat      360

ggtggtggtg attatgctct gggggctttt gatccctggg gcccaggcac cctggtcacc      420

gtctcctca                                                              429


<210>  2
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: CDR fragment

<400>  2
cgctatgatt atatgtgc                                                     18


<210>  3
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: CDR fragment

<400>  3
agtatttatg ttggtagtgg tgtcacttac tactcgacct gggcgagagg c                51


<210>  4
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: CDR fragment

<400>  4
tttcatggtc atggtggtgg tgattatgct ctgggggctt ttgatccc                    48


<210>  5
<211>  98
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Heavy chain antibody

<400>  5
gggcaaccta aggctccatc agtcttccca ctggccccct gctgcgggga cacacccagc       60

tccacggtga ccctgggctg cctggtcaaa gggtacct                               98


<210>  6
<211>  143
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Heavy chain antibody

<400>  6

Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly 
1               5                   10                  15      


Val Gln Cys Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro 
            20                  25                  30          


Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser 
        35                  40                  45              


Arg Tyr Asp Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 
    50                  55                  60                  


Glu Trp Ile Ala Ser Ile Tyr Val Gly Ser Gly Val Thr Tyr Tyr Ser 
65                  70                  75                  80  


Thr Trp Ala Arg Gly Arg Phe Ala Ile Ser Gln Thr Ser Ser Thr Thr 
                85                  90                  95      


Met Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr 
            100                 105                 110         


Phe Cys Ala Arg Phe His Gly His Gly Gly Gly Asp Tyr Ala Leu Gly 
        115                 120                 125             


Ala Phe Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser 
    130                 135                 140             


<210>  7
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Heavy chain antibody fragment

<400>  7

Arg Tyr Asp Tyr Met Cys 
1               5       


<210>  8
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence:  Heavy chain antibody 
       fragment

<400>  8

Ser Ile Tyr Val Gly Ser Gly Val Thr Tyr Tyr Ser Thr Trp Ala Arg 
1               5                   10                  15      


Gly 
    


<210>  9
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence:  Heavy chain antibody 
       fragment

<400>  9

Phe His Gly His Gly Gly Gly Asp Tyr Ala Leu Gly Ala Phe Asp Pro 
1               5                   10                  15      


<210>  10
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence:  Heavy chain constant region

<400>  10

Gly Gln Pro Lys Ala Pro Ser Val Phe Pro Leu Ala Pro Cys Cys Gly 
1               5                   10                  15      


Asp Thr Pro Ser Ser Thr Val Thr Leu Gly Cys Leu Val Lys Gly Tyr 
            20                  25                  30          


<210>  11
<211>  396
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Light chain antibody

<400>  11
atggacacga gggcccccac tcagctgctg gggctcctgc tgctctggct cccaggtgcc       60

agatgtgcct atgatatgac ccagactcca gcctccgtgt ctgcagctgt gggaggcaca      120

gtcaccatca attgccaggc cagtcagagc atcagcaacc tcttagcctg gtatcagcag      180

aaaccagggc agcctcccaa gctcctgatc tattctgcat ccactctggc atctggggtc      240

ccatcgcggt tcaaaggcag tggatctggg acacagttca ctctcaccat cagcgacctg      300

gagtgtgccg atgctgccac ttactactgt cagcagggtt atgatggtat tggtgttgta      360

aattttttcg gcggagggac cgaggtggtg gtcaaa                                396


<210>  12
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Light chain antibody fragment

<400>  12
caggccagtc agagcatcag caacctctta gcc                                    33


<210>  13
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Light chain antibody fragment

<400>  13
tctgcatcca ctctggcatc t                                                 21


<210>  14
<211>  36
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Light chain antibody fragment

<400>  14
cagcagggtt atgatggtat tggtgttgta aatttt                                 36


<210>  15
<211>  315
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Light chain antibody

<400>  15
ggtgatccag ttgcacctac tgtcctcatc ttcccaccag ctgctgatca ggtggcaact       60

ggaacagtca ccatcgtgtg tgtggcgaat aaatactttc ccgatgtcac cgtcacctgg      120

gaggtggatg gcaccaccca aacaactggc atcgagaaca gtaaaacacc gcagaattct      180

gcagattgta cctacaacct cagcagcact ctgacactga ccagcacaca gtacaacagc      240

cacaaagagt acacctgcaa ggtgacccag ggcacgacct cagtcgtcca gagcttcaat      300

aggggtgact gttag                                                       315


<210>  16
<211>  132
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Light chain antibody

<400>  16

Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp 
1               5                   10                  15      


Leu Pro Gly Ala Arg Cys Ala Tyr Asp Met Thr Gln Thr Pro Ala Ser 
            20                  25                  30          


Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ala Ser 
        35                  40                  45              


Gln Ser Ile Ser Asn Leu Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
    50                  55                  60                  


Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val 
65                  70                  75                  80  


Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr 
                85                  90                  95      


Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gln 
            100                 105                 110         


Gly Tyr Asp Gly Ile Gly Val Val Asn Phe Phe Gly Gly Gly Thr Glu 
        115                 120                 125             


Val Val Val Lys 
    130         


<210>  17
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Light chain antibody fragment

<400>  17

Gln Ala Ser Gln Ser Ile Ser Asn Leu Leu Ala 
1               5                   10      


<210>  18
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Light chain antibody fragment

<400>  18

Ser Ala Ser Thr Leu Ala Ser 
1               5           


<210>  19
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Light chain antibody fragment

<400>  19

Gln Gln Gly Tyr Asp Gly Ile Gly Val Val Asn Phe 
1               5                   10          


<210>  20
<211>  104
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Light chain constant region

<400>  20

Gly Asp Pro Val Ala Pro Thr Val Leu Ile Phe Pro Pro Ala Ala Asp 
1               5                   10                  15      


Gln Val Ala Thr Gly Thr Val Thr Ile Val Cys Val Ala Asn Lys Tyr 
            20                  25                  30          


Phe Pro Asp Val Thr Val Thr Trp Glu Val Asp Gly Thr Thr Gln Thr 
        35                  40                  45              


Thr Gly Ile Glu Asn Ser Lys Thr Pro Gln Asn Ser Ala Asp Cys Thr 
    50                  55                  60                  


Tyr Asn Leu Ser Ser Thr Leu Thr Leu Thr Ser Thr Gln Tyr Asn Ser 
65                  70                  75                  80  


His Lys Glu Tyr Thr Cys Lys Val Thr Gln Gly Thr Thr Ser Val Val 
                85                  90                  95      


Gln Ser Phe Asn Arg Gly Asp Cys 
            100                 


